Ebola survivors get vaccine shot in groundbreaking immunity study
NCT ID NCT05992480
Summary
This study is testing how well Ebola survivors respond to the approved ERVEBO® vaccine compared to people receiving it for the first time. Researchers want to see if survivors get a strong, lasting immune boost from the vaccine, since their natural immunity can fade over time. The study involves 40 adults in Sierra Leone—half are Ebola survivors and half are people with no prior exposure—who will receive the vaccine and be monitored for six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kenema Government Hospital
RECRUITINGKenema, Eastern Province, Sierra Leone
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.